<DOC>
	<DOCNO>NCT00144014</DOCNO>
	<brief_summary>A Phase II study evaluate safety efficacy five dose level study drug acute ischaemic stroke</brief_summary>
	<brief_title>Safety Efficacy Study Acute Ischaemic Stroke</brief_title>
	<detailed_description>An open label , dose escalation study patient acute ischaemic stroke receive single intravenous dose study drug . There five dose level group 10 patient . Escalation high dos occur follow review safety data previous dose .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<criteria>Summary 1 . Onset new neurological sign stroke within 3 9 hour time initiation treatment 2 . Aged 18 3 . Provide consent 4 . Cerebral CT scan show finding early ischaemic change consistent clinical diagnosis ASPECT score 5 10 inclusive . 5 . NIHSS score great 5 less equal 20 . Summary 1 . Coma 2 . Stroke unknown time onset 3 . Minor stroke symptom sings ( &lt; 6 point NIHSS ) rapidly improve time randomisation . 4 . Major stroke symptom sign ( &gt; 20 NIHSS ) 5 . History stroke previous 6 week 6 . History brain tumours 7 . CT scan result ASPECT score &lt; 5 8 . Haemorrhagic risk 9 . Abnormal laboratory value 10 . Positive urine pregnancy test , lactation parturition within previous 30 day . 11 . Weight &gt; 135 kg 12 . Uncontrolled hypertension . 13 . Raised blood glucose 14 . History current serious illness 15 . Participation another clinical trial within 4 week drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Acute</keyword>
	<keyword>Ischaemic</keyword>
	<keyword>Stroke</keyword>
</DOC>